Test Price
2,800 AED✅ Home Collection Available
COL6A3 Gene DYT27 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين COL6A3 DYT27 بتقنية التسلسل الجيني فائق الإنتاجية (NGS) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Clinical Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Hospital‑Grade Home Collection by DHA‑licensed phlebotomists with ISO‑Certified Cold‑Chain handling for whole blood, FTA cards, or extracted DNA.
- Clinical Guidance: Complimentary telephonic post‑test clinical correlation session to interpret results with a specialist advisor.
- Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731
تحليل جيني متقدم معتمد من هيئة الصحة بدبي لتحديد الطفرات المسببة لمرض ديستونيا 27 (DYT27) في جين COL6A3 باستخدام تقنية التسلسل فائق الإنتاجية، مع دقة تشخيصية معززة تتجاوز المختبرات التقليدية.
Licensed Molecular Lab
2800 AED
Results in 3–4 Weeks
License No. 9834453
Clinical Test Overview
This Next‑Generation Sequencing (NGS) assay scrutinizes the entire coding region of the COL6A3 gene to identify pathogenic variants linked to autosomal dominant dystonia type 27 (DYT27). Designed for UAE patients with early‑onset isolated dystonia, the test empowers neurologists and clinical geneticists with precise molecular diagnosis, enabling tailored treatment strategies and informed family counselling.
| Feature | Our COL6A3 NGS Test | Closest Alternative (Targeted Dystonia Panel) |
|---|---|---|
| Precision | Full gene sequencing via NGS with 99.9% analytical sensitivity | Limited to pre‑selected exonic hotspots; may miss novel or deep intronic variants |
| Methodology | Illumina® NovaSeq X‑grade chemistry, verified with Sanger confirmation | Multiplex ligation‑dependent probe amplification (MLPA) or small gene panels |
| Turnaround | 3–4 weeks with pre‑test genetic counselling | 4–8 weeks, often without integrated counselling |
Physician Insight & Safety Protocol
“As a clinician, I recognize that facing a potential genetic movement disorder can be profoundly unsettling. This COL6A3 NGS test provides the molecular certainty you and your family need to plan the next steps—whether that’s targeted therapy or informed genetic counselling. Always interpret the result together with your neurologist to ensure clinical correlation.”
— Dr. PRABHAKAR REDDY, DHA Licensed (No. 61713011)
Exclusion Criteria & Emergency Red Flags
- Not intended for acute dystonic crisis—seek emergency care immediately if severe muscle spasms impair breathing or swallowing.
- Requires patient clinical stability; this is not a stand‑alone screening tool for asymptomatic minors without genetic counselling and parental consent (UAE CDS Law 2026).
- Red Flag Signs: sudden loss of consciousness, autonomic instability (tachycardia, hypertension), or rapid progression of neurological deficits.
Medication Warning
Do not discontinue or modify any prescribed anti‑dystonic or neurological medication without the explicit instruction of your treating physician. An abrupt change may precipitate a severe dystonic storm.
Pre‑Test Requirements (Required)
- A mandatory genetic counselling session to construct a detailed pedigree of family members affected with COL6A3‑linked dystonia.
- Comprehensive clinical history documentation, including onset age, trigger factors, and previous imaging/EMG results.
- Sample types accepted: Whole Blood (EDTA), Extracted DNA (≥1 µg), or FTA Card Blood Spot. All collected via DHA‑approved mobile phlebotomy.
Frequently Asked Questions (Patient Guidance)
What exactly is the COL6A3 DYT27 genetic test and why is it recommended?
Direct Answer: This advanced NGS test decodes your COL6A3 gene to detect mutations causing dystonia type 27, a rare inherited movement disorder that typically appears in childhood or adolescence.
يقوم هذا الفحص الجيني المتقدم بقراءة شاملة لجين COL6A3 للكشف عن الطفرات المسببة لمرض ديستونيا 27 الوراثي، مما يوفر تشخيصاً دقيقاً يوجه خطة العلاج والاستشارات العائلية.
How is the sample collected and when will I receive the results?
Direct Answer: A DHA‑licensed phlebotomist visits your home to collect a small blood sample or FTA card using sterile, cold‑chain transport; results are ready in 3–4 weeks.
يتم جمع العينة بطريقة منزلية معقمة بواسطة فني معتمد من هيئة الصحة بدبي، وتظهر النتائج خلال ٣ إلى ٤ أسابيع عبر بوابة إلكترونية آمنة.
Does UAE health insurance cover the COL6A3 DYT27?
Direct Answer: Most UAE insurers cover medically necessary genetic tests; we verify your eligibility instantly via WhatsApp at +971 54 548 8731 before scheduling.
تغطي معظم شركات التأمين في الإمارات الفحوصات الجينية الضرورية طبياً، ويمكنك التحقق من التغطية فوراً عبر واتساب على الرقم ٠٥٤٥٤٨٨٧٣١+.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians